Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Mar 1.

Published in final edited form as: Ann Neurol. 2022 Jan 25;91(3):424–435. doi: 10.1002/ana.26302

Table 4.

Characteristics of DBS subjects

	GBA with DBS (n=58)	Non-GBA with DBS (n=98)	p
Years from motor onset to DBS	10.54 (5.17)	11.54 (5.79)	0.28
Years of DBS	4.95 (3.96)	4.39 (4.21)	0.41
Pre-DBS
MDRS	139.18⁴ (3.60)	139.18 (3.83)	1.0
UPDRS-III (OFF medication)	35.48¹⁵ (13.37)	33.59¹² (14.41)	0.47
UPDRS-III (ON medication)	14.27⁸ (8.51)	12.87¹² (9.66)	0.39
% change UPDRS-III OFF vs. ON medication	58.22¹⁵ (30.20)	63.59¹³ (22.26)	0.25
LEDD	1079.97³⁰ (461.88)	1191.46³⁹ (474.35)	0.30
Post-DBS motor function
UPDRS-III (ON medication/ON stimulation)	12.88³⁰ (10.78)	11.71³⁵ (9.71)	0.61
% change UPDRS-III (pre-DBS OFF medication vs. post-DBS ON medication/ON stimulation)	57.92³⁶ (41.49)	61.23³⁹ (32.78)	0.71
years post-DBS (UPDRS)	1.69³⁰ (1.54)	1.59³² (1.23)	0.74
Post-DBS medication burden
LEDD reduction	496.92³³ (316.49)	458.87⁴⁶ (382.38)	0.66
% change LEDD pre vs. post-DBS	49.46³³ (40.79)	60.96⁴⁸ (27.24)	0.15
Years post-DBS	1.54³³ (1.24)	1.48⁴⁶ (1.13)	0.84

Superscript indicates number of subjects with missing values